Fierce Pharma2d
Another big payday for O'Day as Gilead boosts his compensation 5% to $23.7M
Gilead CEO Daniel O’Day saw another rise in his pay in 2024, reflecting the steadily upward trajectory of the company since ...
Gilead Sciences CEO's pay climbed to $23.7 million
Gilead Sciences Inc. CEO Daniel O'Day's compensation rose 4.8% last year to $23.7 million — roughly $97 for every buck made ...
Gilead’s HIV Treatments Could Face Headwinds. Why the Stock Will Still Rise.
Gilead Sciences stock has room to climb, and investors shouldn’t overlook the company’s impressive record in navigating HIV policy, Citi Research says. Analysts led by Geoff Meacham reiterated a Buy ...
Fierce Pharma3d
Potential federal budget cuts won't rock Gilead's HIV boat too much: analysts
News of potential federal budget cuts impacting HIV drugs in the U.S. was quickly reflected in a dip in share prices for top ...
A Closer Look at Gilead Sciences's Options Market Dynamics
Investors with a lot of money to spend have taken a bearish stance on Gilead Sciences GILD. And retail traders should know.
Gilead put volume heavy and directionally bearish
Bearish flow noted in Gilead (GILD) with 1,949 puts trading, or 1.3x expected. Most active are 4/4 weekly 107 puts and Apr-25 109 puts, with ...
Explore more
3GILD : What Analysts Are Saying About Gilead Sciences Stock
Rating: Analysts assign qualitative assessments to stocks, ranging from 'Outperform' to 'Underperform'. These ratings convey the analysts' expectations for the relative performance of Gilead Sciences ...